Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Phase of Trial: Phase IV
Latest Information Update: 15 Sep 2016
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Allergan
- 31 Aug 2016 Status changed from active, no longer recruiting to completed.
- 08 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 30 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.